biologic

Eylea HD

aflibercept

Loss of exclusivityAugust 2035projected — 12-year biologic exclusivity estimate
CompanyRegeneron PharmaceuticalsView the full company profile on CliffBio

Drug detail

Brand nameEylea HD
Active ingredientaflibercept
Strength8MG/0.07ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalAugust 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Eylea HD patent cliff — loss of exclusivity August 2035 | CliffBio